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When prescribing hemodialysis in children, the clinician should ﬁrst establish an adequate regimen, before seeking to optimize
the treatment (Fischbach et al. 2005). A complete dialysis dose should consist of a urea dialysis dose and a determined convective
volume. Intensiﬁed and more frequent dialysis regimens should not be considered exclusively as rescue therapy. Interestingly, a
recent single-center study demonstrated that frequent on-line HDF provides an optimal dialysis prescription, both in terms of
blood pressure control (and therefore avoidance of left ventricular hypertrophy), and catch-up growth, that is, no malnutrition
or cachexia and less resistance to growth hormone. Nevertheless, this one-center experience would beneﬁt from a prospective
randomized study.
1.Introduction
Over the past 20 years, children receiving dialysis have bene-
ﬁted not only from advances in modern technology, but also
from improvements in clinical management. Nevertheless,
conventional haemodialysis performed three times a week
still results in an increased risk of cardiovascular morbidity
and impaired growth in children [1, 2]. The “HEMO” study
[3] found that the prescription of a high urea dialysis dose in
hemodialysis performed three times a week in adults failed
to result in an improvement in clinical outcome. Therefore,
“a complete dialysis dose” should be prescribed, that is, not
only a urea dialysis dose (a small solute diﬀusive clearance)
[4] but also a convective dialysis volume (middle molecule
uremic toxin clearance) [5]. At present, despite great interest
and feasibility, hemodiaﬁltration is rarely performed [6–8].
However, the case for performing intensiﬁed and/or more
frequent hemodialysis regimens in both children [9–13]
and adults has been put forward [14–17]. All intensiﬁed
treatment modalities, ranging from daily procedures to long
intermittent hemodialysis sessions, clearly improve patient
outcome in terms of mortality and morbidity. In children,
daily on-line hemodiaﬁltration has even been found to
promote catch-up growth [9, 18]. However, intensive and
daily dialysis is rarely performed as a long-term dialysis
regimen for “all patients” as it is often only considered as a
rescue therapy [15].
2.Urea DialysisDose For Children
Urea kinetic modeling is generally accepted as a method
for evaluating the dialysis dose prescribed [19], despite the
fact that it is of limited value in the assessment of dialysis
adequacy [4].
Quantiﬁcation of dialysis is based on a urea dialysis
dose, that is, Kt/V, (dialyzer urea clearance (K) multiplied
by duration (t) of the dialysis session and divided by
urea volume (V) of distribution. On-line urea clearance
measurements, which are currently available on modern
dialysis machines, make it easy to calculate the dialysis dose
(Kt) and, thus, allow the clinician to calculate the Kt/V
for each session, providing an estimation of V which is
assumedtobeequaltothetotalbodywater.Impedancemetry
[20] is of clinical interest when estimating V,a si td o e s
not require blood sampling to be performed. However, it2 International Journal of Nephrology
does require the use and availability of a speciﬁc machine
(BCM, Fresenius Medical Care). The use of anthropometric
formulas to calculate “V” has been found to be less accurate
especially in children [19]. An indirect method of calculating
“V” can be achieved using the ratio Kt/Kt/V [20], where
Kt is obtained from the ionic dialysance provided by the
dialysis monitor, and Kt/V is obtained from the second
generation of Daugirdas formula [19], which requires blood
samples to be taken before and after the dialysis session.
The on-line urea Kt/V assessment performed by the dialysis
monitor gives out a single pool Kt/V (spKt/V)[ 19], with
a proposed target dose of 1.4 per dialysis session in anuric
patients [19, 21]. Nevertheless, spKt/V does not take into
account postdialytic urea rebound. Therefore, formulas for
estimating the equilibrated Kt/V (eKt/V)a r ea v a i l a b l e[ 4,
19, 21]. Due to the need for postdialytic blood sampling, in
practice spKt/V is a clinically acceptable way of monitoring
HD adequacy, at least in a thrice-weekly hemodialysis
regimen. In cases where hemodialysis is performed more
frequently, standard Kt/V (stKt/V)s h o u l db ec a l c u l a t e d
[22]. This formula integrates spKt/V and eKt/V in order to
account for urea peaks and valleys. A dialysis dose based
on body surface area (SAN-stKt/V) has been suggested to
be a more accurate way of determining the urea dialysis
dose required in children: a dose over 2.45 [23]s h o u l d
be considered to be an optimal dialysis dose, promoting
c a t c hu ps t a t u r a lg r o w t hi nc h i l d r e no nc h r o n i cd i a l y s i s .
Nevertheless,acompletedialysisdose[5]shouldbepr eferr ed
to an urea dialysis dose, “only” a diﬀusive dialysis dose
[5]. The “complete dialysis dose” is diﬃcult to deﬁne and
stays under discussion [4, 5]: beside the urea dialysis dose,
ad i ﬀusive dialysis dose, a convective dialysis dose could be
proposed [6, 15, 24], based on phosphate dialytic removal
and on the achieved beta 2 microglobulinemia.
3.ConvectiveDialysis Dose: TheConvective
VolumeperDialysis Session
Uremic toxins can be categorized into three groups: free
water soluble low-molecular-weight solutes such as urea,
middle-sized solutes such as beta 2 microglobulin (β2m ) ,
and protein-bound solutes such as p-cresol acid [24]. The
phosphate ion is small, but not “free” as it is surrounded by
water molecules; therefore, it has a clearance proﬁle similar
tothatofthemiddle-sized molecules.The removal ofuremic
toxins by dialysis relies upon a combination of the diﬀusion
process, convective mass transport, and membrane adsorp-
tion [25]. Haemodialysis (HD) provides optimal removal
of low-molecular-weight uremic toxins such as urea due to
the diﬀusive ﬂow of solutes. Conversely, the convective ﬂow
of solutes which mainly occurs in hemoﬁltration (HF) and
hemodiaﬁltration (HDF) results in the removal of middle-
sized and large molecules. Convection and diﬀusion are
presented as two separate phenomena, but in practice they
are on a continuous interference. Nevertheless, the concept
ofacompletedialysisdose[5],which includesnotonlyaurea
dialysis dose, that is, Kt/V urea, but also a convective dialysis
dose, that is, the convective volume achieved per dialysis
session, maybe ofimportance in termsofpatientoutcome—
in particular resulting in an improvement in cardiovascular
mortality [6, 26].
Hemodiaﬁltration is a combination of HD and HF per-
formed during the same procedure, allowing a determined
convective ﬂow per dialysis session. The weight loss that
arises when HD occurs only ensures a convective ﬂow equal
to the ultraﬁltration rate, that is, a small convective volume.
During conventional HD with high-ﬂux ﬁlters, “internal”
HDF occurs due to back ﬁltration of the dialysate, providing
only a slightly larger but nondetermined convective volume.
Moreover, the dialysate used is not always a sterile, nonpyro-
genic substitution ﬂuid, and therefore may provoke systemic
inﬂammation [28, 29]. Altogether, on-line hemodiaﬁltra-




on both solute removal and clinical outcome. HDF oﬀers
improved control of phosphate when compared to both HD
and high-ﬂux HD [6, 7]. Predialysis β2ms e r u ml e v e l sa r e
decreased during OL-HDF; the β2md i a l y t i cr e m o v a lc o r -
relates with the convective volume achieved. High-eﬃciency
HDF, as deﬁned in adult patients in postdilution mode using
a convective dose of more than 15L per session, is superior
to low-eﬃciency HDF both in terms of solute removal and
patient outcome [6, 7]. As demonstrated by a recent single
centre study [18], when performed on a daily basis, on-line
HDF using a convective volume in pre dilution mode of 18
to 27L/m2 per procedure even promotes catch up growth in
c h i l d r e n .A tp r e s e n t ,i ti sn o tk n o w ni ft h ed i ﬀerent intensive
hemodialysis regimens available are equivalent in terms of
their growth promoting capacity [11, 21].
4.HemodialysisFluidsPurity
The purity, in terms of microbial contaminants measured
as colony forming units (CFU) and endotoxins units (EU),
is recorded for the diﬀerent ﬂuids used in the dialysis
procedure [7]. The purity should be carefully assessed in
order to limit the risk of patient’s systemic inﬂammation,
in the clinical setting illustrated by the surrogate parameter
of an elevated CRP. Standard quality dialysis ﬂuid (bacterial
count <100CFU/ml; endotoxin units <0.50EU/ml) is not
appropriate for use with high-ﬂux ﬁlters for HD, due to
t h ei n t e r n a lc o n v e c t i v eﬂ o w ,t h a ti s ,t h eb a c k ﬁ l t r a t i o n .H i g h -
ﬂux membranes require the use of ultrapure dialysate,
that is, bacterial count <0.1CFU/mL; endotoxin count
<0.05UI/mL. For “at risk” patients, the current European
guidelines recommend the use of highly permeable mem-
branes in HD [27]. This results in restricted “internal” HDF,
as only a small nondetermined convective volume is used.
5. Blood Pressure Control,
CardiovascularDisease
Repeated conventional dialysis sessions have an additive
eﬀect which contributes, towards the cardiovascular riskInternational Journal of Nephrology 3
Table 1: Adequate hemodialysis prescription for children: more than a urea dialysis dose (adapted from [4, 5, 11, 19, 27]).
(i) Hemodialysis should be performed in a pediatric dialysis center, in order to ensure optimal care and child development (nutrition,
growth, education)
(ii) A complete dialysis dose should be prescribed, not only a urea dialysis dose, that is, sp Kt/V > 1.4 in anuric patients, but also a high
convective volume. Phosphate and β2 m can be used as markers for the removal of “middle-sized uremic molecules.”
(iii)
Prefer biocompatible materials where possible, that is, high-ﬂux membranes which provide enhanced molecular permeability.
High-ﬂux membranes, especially in cases of high hydraulic permeability, require the use of ultrapure dialysate, that is, a bacterial
count <0.1CFU/mL and an endotoxin count <0.05UI/mL.
(iv) Control blood pressure and aim for prevention of cardiovascular sequelae such as left ventricular hypertrophy, left ventricular
dysfunction, coronary artery calciﬁcations,and vascular stiﬀness.
(v) Ensure optimal nutrition, that is, limit malnutrition and cachexia in order to avoid muscle wasting and to promote growth and
development.
(vi) Propose an intensiﬁed hemodialysis regimen, that is, longer and/or more frequent dialysis in center or at home, not only for use as a
rescue therapy.
(vii)
Deliver the highest standard of dialysis possible in all cases, that is, biocompatibility of the material used, monitor the purity of the
dialysate, and use a controlled determined convective ﬂow instead of an internal, small, nondetermined ﬂow with backﬁltration into
the dialyzer.
proﬁle in children, that is, morbidity and mortality. Adverse
eﬀects related to dialysis include: high blood pressure,
left ventricular hypertrophy or impaired left ventricular
function, elevated calcium/phosphate resulting in calci-
ﬁcation of blood vessels (particularly vascular/coronnary
calciﬁcations), and systemic inﬂammation. The above list
accounts for the vast majority of dialysis related risks to
the cardiovascular system, contributing towards increased
morbidity and mortality [2, 32].
Inchildrenonchronicconventionalhemodialysis, hyper-
tension is common. For example, 79% of children on HD
in the United States have an elevated BP at the start of
the dialysis session [33]. A further study found that Left
ventricular hypertrophy (LVH) was worryingly common
(82% of patients) in children at the initiation of dialysis, and
remained frequent (82%) and severe (59%) after 2 years of
maintenance conventional hemodialysis [34].
In children on conventional HD, LVH may be improved
[35]by optimizingthe sodiumbalance, for example,by strict
dietary control of sodium intake, dry weight achievement,
and supplementary dialysis time. Overall however, inten-
siﬁed hemodialysis regimens should not be disregarded in
the hope of improving cardiovascular health [11], and they
should, therefore, not be considered exclusively as rescue
therapy [15].
6.ProteinWasting:Cachexia
Malnutrition is common amongst children on chronic
haemodialysis. However, they are not only malnourished—
which infersthatdietary supplementationwould becurative,
buttheyarealso cachexic(i.e.,in astateofproteinloss).Mal-
nutrition and cachexia combined are two important factors
which contribute towards the protein wasting seen in uremic
patients [36]. Conventional hemodialysis performed three
times a week requires patients to stick to a restrictive diet
which limits the intake of protein, water, sodium, potassium,
and phosphate, whilst at the same time maintaining an
adequatecalorieintake.Duetolimiteduremictoxinremoval,
chelators of phosphate and potassium are often prescribed-
but these are also factors which contribute towards anorexia,
that is, malnutrition. Conversely, if the dialysed child has
a good appetite, he is at risk of increased weight gain
between dialysis sessions and of raised blood phosphate or
potassium levels and of major metabolic acidosis. In such
circumstances, the duration of the dialysis procedure is often
increased from 4 to 5 hours, and sometimes an additional
dialysis session later in the week may be required. The
child on long-term dialysis often considers these changes or
adaptions to be a form of punishment, and he responds in
turnbyfasting andbecomingincreasingly lesscompliantand
more opposed to the procedure. Aside from malnutrition,
protein catabolism is an independent factor which plays a
major role in the muscle wasting and poor linear growth
that result despite rh GH therapy. Loss of protein stores, that
is, more cachexia than malnutrition [37] is a multifactorial
event, caused by: inﬂammation [38], acidosis, uremic toxin
retention, and volume overload, that is, poor blood pressure
control. Malnutrition and cachexia should be limited by
more intensive and frequent hemodialysis. Interesting, on-
line HDF performed on a daily basis has been found to
reversebothcachexiaandmalnutrition andtopromotecatch
up growth in children [18].
7.Conclusions
In children, an adequate hemodialysis prescription requires
more than simply a urea dialysis dose (Table 1). If eco-
nomically feasible, high-ﬂux membranes should be used
in combination with ultrapure disposable dialysate. On-
line hemodiaﬁltration, that is, substitution ﬂuid prepared
from ultraﬁltration of the ultrapure dialysate, is a safe
routine replacement therapy which has a positive impact
not only on the removal of solutes such as phosphate or
β2 m, but also on clinical outcome. Intensiﬁed and more
frequent hemodialysis regimens, that is, high-ﬂux HD or4 International Journal of Nephrology
on-lineHDF,provideadequatehemodialysisinchildren,and
should, therefore, not exclusively be used as rescue therapy.
Nevertheless,inyoungchildrenwith renalresidualclearance,
peritoneal dialysis remains an excellent choice of chronic at
home dialysis modality.
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